Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268980 | 0.97 | PIK3CD (0.35) | PIK3CDALKDGAT1SYKKCNH2 | |
| SCHEMBL31268789 | 0.94 | PIK3CD (0.37) | PIK3CDALKSYKKCNH2SCN5A | |
| SCHEMBL31268834 | 0.93 | DGAT1 (0.43) | PIK3CDDGAT1KCNH2SCN5ASCN9A | |
| SCHEMBL31268868 | 0.92 | PIK3CD (0.39) | PIK3CDDGAT1SYKKCNH2SCN5A | |
| SCHEMBL31269016 | 0.92 | PIK3CD (0.35) | PIK3CDDGAT1SYKKCNH2SCN5A | |
| SCHEMBL31268975 | 0.91 | PIK3CD (0.37) | PIK3CDSYKKCNH2SCN5ASCN9A | |
| SCHEMBL31268979 | 0.91 | PIK3CD (0.35) | PIK3CDDGAT1KCNH2SCN5ASCN9A | |
| SCHEMBL31269022 | 0.91 | PIK3CD (0.36) | PIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL31269139 | 0.91 | PIK3CD (0.39) | PIK3CDDGAT1SYKKCNH2SCN5A | |
| SCHEMBL31269076 | 0.89 | PIK3CD (0.37) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |